It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
GTP-cyclohydrolase deficiency in dopa-responsive dystonia (DRD) patients impairs the biosynthesis of dopamine, but also of serotonin. The high prevalence of non-motor symptoms suggests involvement of the serotonergic pathway. Our study aimed to investigate the serotonergic system in vivo in the brain of`DRD patients and correlate this to (non-)motor symptoms. Dynamic [11C]DASB PET scans, a marker of serotonin transporter availability, were performed. Ten DRD, 14 cervical dystonia patients and 12 controls were included. Univariate- and network-analysis did not show differences in binding between DRD patients compared to controls. Sleep disturbances were correlated with binding in the dorsal raphe nucleus (all participants: rs = 0.45, p = 0.04; patients: rs = 0.64, p = 0.05) and participants with a psychiatric disorder had a lower binding in the hippocampus (all participants: p = 0.00; patients: p = 0.06). Post-hoc analysis with correction for psychiatric co-morbidity showed a significant difference in binding in the hippocampus between DRD patients and controls (p = 0.00). This suggests that psychiatric symptoms might mask the altered serotonergic metabolism in DRD patients, but definite conclusions are difficult as psychiatry is considered part of the phenotype. We hypothesize that an imbalance between different neurotransmitter systems is responsible for the non-motor symptoms, and further research investigating multiple neurotransmitters and psychiatry in DRD is necessary.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 University Medical Center Groningen, University of Groningen, Department of Neurology, Groningen, The Netherlands (GRID:grid.4830.f) (ISNI:0000 0004 0407 1981); University Medical Center Groningen (UMCG), Expertise Center Movement Disorders Groningen, Groningen, The Netherlands (GRID:grid.4494.d) (ISNI:0000 0000 9558 4598)
2 University Medical Center Groningen (UMCG), University of Groningen, Department of Nuclear Medicine and Molecular Imaging, Groningen, The Netherlands (GRID:grid.4830.f) (ISNI:0000 0004 0407 1981)
3 University Medical Center Groningen, University of Groningen, Department of Neurology, Groningen, The Netherlands (GRID:grid.4830.f) (ISNI:0000 0004 0407 1981)
4 University Medical Center Groningen (UMCG), Expertise Center Movement Disorders Groningen, Groningen, The Netherlands (GRID:grid.4494.d) (ISNI:0000 0000 9558 4598); Lund University, Department of Clinical Sciences, Lund, Sweden (GRID:grid.4514.4) (ISNI:0000 0001 0930 2361)